Free tool
Oncology stocks
We cover 105 companies grouped under the Oncology theme. The median market value in the group is $26.64M. Across the group, the median move over the past trading day is +1.01%. 41% of the 104 with a 200-day average trade above it. Price change over the past year runs from −89.8% to +208.7% across the middle 80 percent of the group, with a median of −31.2%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
105 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +67.40% |
| CGON | CG Oncology, Inc. | $7.00B | Mid cap | +210.58% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +79.61% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +212.13% |
| ERAS | Erasca, Inc. | $6.16B | Mid cap | +1016.98% |
| RLAY | Relay Therapeutics, Inc. | $4.51B | Mid cap | +486.04% |
| ELVN | Enliven Therapeutics, Inc. | $4.48B | Mid cap | +205.89% |
| CELC | Celcuity Inc. | $4.44B | Mid cap | +87.35% |
| TNGX | Tango Therapeutics, Inc. | $4.13B | Mid cap | +264.73% |
| IDYA | IDEAYA Biosciences, Inc. | $4.10B | Mid cap | +71.91% |
| RCUS | Arcus Biosciences, Inc. | $4.02B | Mid cap | +211.03% |
| TLX | Telix Pharmaceuticals Limited | $3.96B | Mid cap | −4.26% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +196.22% |
| ZLAB | Zai Lab Limited | $2.94B | Mid cap | −23.10% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.89B | Mid cap | +637.70% |
| NRIX | Nurix Therapeutics, Inc. | $2.73B | Mid cap | +178.70% |
| NUVB | Nuvation Bio Inc. | $2.49B | Mid cap | +146.53% |
| URGN | UroGen Pharma Ltd. | $2.27B | Mid cap | +150.59% |
| XNCR | Xencor, Inc. Common Stock | $2.18B | Mid cap | +265.79% |
| HCM | HUTCHMED (China) Limited | $2.13B | Mid cap | −23.04% |
| NBTX | Nanobiotix S.A. | $2.11B | Mid cap | +321.42% |
| NVCR | NovoCure Limited | $2.05B | Mid cap | +50.60% |
| JATT | JATT II Acquisition Corp. | $97.15M | Micro cap | +18.62% |
| ACRV | Acrivon Therapeutics, Inc. | $93.42M | Micro cap | +63.91% |
| MAIA | MAIA Biotechnology, Inc. | $85.78M | Micro cap | −10.76% |
| CTOR | Citius Oncology, Inc. | $85.68M | Micro cap | −57.14% |
| VRCA | Verrica Pharmaceuticals Inc. | $83.66M | Micro cap | −17.53% |
| CRDF | Cardiff Oncology, Inc. | $79.35M | Micro cap | −53.85% |
| ELTX | Elicio Therapeutics, Inc. | $79.11M | Micro cap | −72.71% |
| APLM | Apollomics, Inc. | $76.75M | Micro cap | +318.64% |
| OSTX | OS Therapies Incorporated | $76.68M | Micro cap | −24.66% |
| PLRX | Pliant Therapeutics, Inc. | $73.69M | Micro cap | −23.49% |
| XBIT | XBiotech Inc. | $70.43M | Micro cap | −28.13% |
| PMVP | PMV Pharmaceuticals, Inc. | $69.76M | Micro cap | −8.10% |
| BOLD | Boundless Bio, Inc. | $67.33M | Micro cap | +160.18% |
| RNXT | RenovoRx, Inc. | $64.08M | Micro cap | +58.13% |
| HRTX | Heron Therapeutics, Inc. | $61.34M | Micro cap | −76.59% |
| XLO | Xilio Therapeutics, Inc. | $59.75M | Micro cap | −7.35% |
| IMMP | Immutep Limited | $56.28M | Micro cap | −77.54% |
| TIL | Instil Bio, Inc. | $51.54M | Micro cap | −69.62% |
| IBO | Impact BioMedical Inc. | $49.62M | Micro cap | −20.79% |
| BKHA | Black Hawk Acquisition Corporation | $49.39M | Micro cap | +8.09% |
| HOWL | Werewolf Therapeutics, Inc. | $42.93M | Micro cap | −35.04% |
| KPTI | Karyopharm Therapeutics Inc. Common Stock | $42.19M | Micro cap | −69.57% |
| CNTX | Context Therapeutics Inc. | $40.00M | Micro cap | −50.13% |
| ATNM | Actinium Pharmaceuticals, Inc. | $33.88M | Micro cap | −39.66% |
| BCTX | BriaCell Therapeutics Corp. | $32.80M | Micro cap | −49.67% |
| KYNB | Kyntra Bio, Inc. | $32.80M | Micro cap | −23.80% |
| BYSI | BeyondSpring Inc. | $29.61M | Micro cap | −60.43% |
| EVAX | Evaxion A/S | $28.36M | Micro cap | +4.49% |
| LTRN | Lantern Pharma Inc. | $27.87M | Micro cap | −52.30% |
| NXTC | NextCure, Inc. | $27.05M | Micro cap | +13.33% |
| PSTV | Plus Therapeutics Inc | $26.64M | Micro cap | −68.67% |
| ATOS | Atossa Therapeutics, Inc. | $26.35M | Micro cap | −76.49% |
| CVM | CEL-SCI Corporation | $26.03M | Micro cap | −85.98% |
| MRKR | Marker Therapeutics, Inc. | $25.34M | Micro cap | +20.63% |
| CLRB | Cellectar Biosciences, Inc. | $24.01M | Micro cap | −45.96% |
| BFRI | Biofrontera Inc. | $22.43M | Micro cap | +63.77% |
| CCM | Concord Medical Services Holdings Limited | $21.49M | Micro cap | −10.65% |
| ABVC | ABVC BioPharma, Inc. | $21.32M | Micro cap | −72.70% |
| ALLR | Allarity Therapeutics, Inc. | $21.16M | Micro cap | +41.34% |
| RADX | Radiopharm Theranostics Limited | $19.55M | Micro cap | −55.71% |
| TPST | Tempest Therapeutics, Inc. | $18.36M | Micro cap | −89.50% |
| CTXR | Citius Pharmaceuticals, Inc. | $16.57M | Micro cap | −52.09% |
| MDCX | Medicus Pharma Ltd. | $16.26M | Micro cap | −87.97% |
| INTS | Intensity Therapeutics, Inc. | $15.98M | Micro cap | −37.24% |
| LSTA | Lisata Therapeutics, Inc. | $15.68M | Micro cap | −31.23% |
| AKTX | Akari Therapeutics, Plc | $14.54M | Micro cap | −77.77% |
| PHIO | Phio Pharmaceuticals Corp. | $13.82M | Micro cap | −41.21% |
| GTBP | GT Biopharma, Inc. | $13.52M | Micro cap | −72.50% |
| BLRX | BioLineRx Ltd. | $12.45M | Micro cap | −25.97% |
| PDSB | PDS Biotechnology Corporation | $12.40M | Micro cap | −82.96% |
| MBRX | Moleculin Biotech, Inc. | $11.90M | Micro cap | −95.75% |
| TOVX | Theriva Biologics, Inc. | $10.90M | Micro cap | −45.33% |
| APRE | Aprea Therapeutics, Inc. | $10.14M | Micro cap | −40.63% |
| LNAI | Lunai Bioworks Inc. | $9.97M | Micro cap | −87.99% |
| XBIO | Xenetic Biosciences, Inc. | $8.93M | Micro cap | +33.57% |
| IMNN | Imunon, Inc. | $8.92M | Micro cap | −73.86% |
| CNSP | CNS Pharmaceuticals, Inc. | $8.48M | Micro cap | −11.31% |
| AIM | AIM ImmunoTech Inc. | $7.73M | Micro cap | −89.97% |
| CURX | Curanex Pharmaceuticals Inc | $7.45M | Micro cap | +18.16% |
| BOLT | Bolt Biotherapeutics, Inc. | $7.42M | Micro cap | −29.28% |
| CANF | Can-Fite BioPharma Ltd. | $7.11M | Micro cap | −74.46% |
| ITOC | iTonic Holdings Ltd. | $6.75M | Micro cap | −51.75% |
| LIMN | Liminatus Pharma, Inc. | $6.19M | Micro cap | +35.59% |
| NCNA | NuCana plc | $6.12M | Micro cap | −56.76% |
| PCSA | Processa Pharmaceuticals, Inc. | $6.09M | Micro cap | −60.36% |
| KAPA | Kairos Pharma, Ltd. | $5.88M | Micro cap | −79.82% |
| BCAB | BioAtla, Inc. | $5.43M | Micro cap | −81.69% |
| HCWB | HCW Biologics Inc. | $4.77M | Micro cap | −53.15% |
| APVO | Aptevo Therapeutics Inc. | $4.43M | Micro cap | −92.81% |
| OSRH | OSR Health, Inc. | $4.09M | Micro cap | −88.47% |
| CRIS | Curis, Inc. | $3.86M | Micro cap | −3.64% |
| RDHL | RedHill Biopharma Ltd. | $3.68M | Micro cap | −55.83% |
| CLDI | Calidi Biotherapeutics, Inc. | $3.39M | Micro cap | −16.03% |
| GOVX | GeoVax Labs, Inc. | $3.34M | Micro cap | −96.61% |
| ARTL | Artelo Biosciences, Inc. | $3.30M | Micro cap | −97.47% |
| NXTS | Nexentis Technologies Inc. | $2.69M | Micro cap | −96.64% |
| PPBT | Purple Biotech Ltd | $2.68M | Micro cap | −92.53% |
| RNAZ | TransCode Therapeutics, Inc. | $2.68M | Micro cap | −74.16% |
| PPCB | Propanc Biopharma, Inc. | $2.57M | Micro cap | −98.66% |
| SLXN | Silexion Therapeutics Corp | $2.04M | Micro cap | −94.88% |
| DCOY | Decoy Therapeutics Inc. | $1.95M | Micro cap | −95.58% |
| BDRX | Biodexa Pharmaceuticals Plc | $1.07M | Micro cap | −96.20% |
| APM | Aptorum Group Ltd | $570.06K | Micro cap | +260.94% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.